secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001104659-24-086740
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway
--------------------------------------------------------------------------------

- Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.
- Total net sales flat at $6.3M; CanGaroo +19% to $2.6M, SimpliDerm +7% to $2.6M.
- FDA clearance for EluPro received; manufacturing commenced; commercial team expanding.
- Cash $18.2M at quarter end; $13.8M additional from post-quarter warrant exercises.
- Adjusted EBITDA loss improved to $2.9M from $3.4M in prior-year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924086740/0001104659-24-086740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924086740/tm2421059d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer